Abstract
The major cause of mortality in patients with both type 1 and type 2 diabetes is cardiovascular complications. Much of this might be attributed to changes in circulating levels of atherogenic and antiatherogenic lipoproteins. An atherogenic profile in patients with type 2 diabetes is termed diabetic dyslipidemia. Lifestyle and medical therapies can be used to treat this condition, leading to major changes in circulating lipids. In this chapter, we review the causes, therapies, and changes in outcomes due to treatment of hyperlipidemias in patients with diabetes.
Author supplied keywords
- Apolipoprotein b (apoB)
- CArdiovascular Disease (CVD)
- Cholesteryl esters
- Chylomicrons
- Ezetimibe
- Fibric acid
- High Density Lipoprotein (HDL)
- Hyperlipidemia
- Lipoprotein Lipase (LpL)
- Low Density Lipoproteins (LDL)
- Niacin
- PCSK9 inhibitors
- Pancreatitis
- Proprotein convertase subtilisin/Kexin type 9 (PCSK9)
- Statins
- Triglycerides
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Very Low Density Lipoproteins (VLDL)
Cite
CITATION STYLE
Freitas Corradi, P., Agrawal, N., Gumaste, N., & Goldberg, I. J. (2017). Dyslipidemia: Pathogenesis and management. In Principles of Diabetes Mellitus: Third Edition (pp. 533–550). Springer International Publishing. https://doi.org/10.1007/978-3-319-18741-9_28
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
